Myriad Genetics (MYGN)
(Delayed Data from NSDQ)
$23.39 USD
+0.06 (0.26%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $23.40 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$23.39 USD
+0.06 (0.26%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $23.40 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum B VGM
Zacks News
Can Solid EPD Business Drive Abbott's (ABT) Q1 Earnings?
by Zacks Equity Research
Abbott (ABT) poised to ride high on strength in EPD business in Q1.
Will Edwards' (EW) Growth in All Lines Drive Q1 Earnings?
by Zacks Equity Research
Edwards Lifesciences (EW) is expected to gain from strength in all the business segments and solid performance across all geographies.
Can Steady Overall Growth Drive Abbott's (ABT) Q1 Earnings?
by Zacks Equity Research
Abbott (ABT) to see impressive year-over-year rise in revenues on strength in all business segments in Q1.
What's in Store for GNC Holdings (GNC) This Earnings Season?
by Zacks Equity Research
GNC Holdings (GNC) likely to witness year-over-year decline in revenues owing to weakness in the U.S. & Canada and Manufacturing/Wholesale segments in Q1.
Intercept Pharmaceuticals (ICPT) in Focus: Stock Moves 9.9% Higher
by Zacks Equity Research
Intercept Pharmaceuticals (ICPT) shares rose nearly 10% in the last trading session, amid huge volumes.
Myriad Genetics' BRACAnalysis Test Platform Gets PMA in Japan
by Zacks Equity Research
Myriad Genetics (MYGN) leaves no stone unturned to boost uptake of BRACAnalysis test and strengthen the Molecular Diagnostics portfolio.
Myriad Genetics (MYGN) Down 3% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Myriad Genetics (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Myriad Genetics Banks on Product Launches, Competition Rife
by Zacks Equity Research
Myriad Genetics (MYGN) focuses on strengthening the Molecular Diagnostics portfolio through product launches.
Myriad Genetics' Positive Study Data May Expand Customer Base
by Zacks Equity Research
Myriad Genetics (MYGN) leaves no stone unturned to drive the uptake of myRisk Hereditary Cancer test and strengthen the Molecular Diagnostics portfolio.
Myriad Genetics (MYGN) Beats on Earnings & Revenues in Q2
by Zacks Equity Research
Myriad Genetics' (MYGN) year over year decline in revenue was in Q2 is disappointing. However, strong demand for GeneSight tests was encouraging.
What's in Store for GNC Holdings (GNC) This Earnings Season?
by Zacks Equity Research
GNC Holdings (GNC) likely to see decline in year-over-year revenues owing to weakness in U.S. & Canada segment in Q4.
Will Covance Drug Development Drive LabCorp (LH) Q4 Earnings?
by Zacks Equity Research
LabCorp (LH) is expected to gain from LabCorp Diagnostics and Covance Drug Development segments in Q4.
ResMed (RMD) Rides on Product Launches, Robust Global Growth
by Zacks Equity Research
ResMed's (RMD) product launches and strategies to gain traction in the sleep-disordered breathing market. This upside is further likely to drive the stock in the future.
Quest Diagnostics to Buy MedXM, Boost Home Health Services
by Zacks Equity Research
Quest Diagnostics (DGX) actively pursues mergers and acquisitions to strengthen hold in the high-potential global home healthcare market.
FDA Nod for QIAGEN's JAK2 Test Boosts Molecular Diagnostic
by Zacks Equity Research
QIAGEN (QGEN) strives to enhance Molecular Diagnostic segment, which was the highest revenue grosser in the last reported quarter.
Can Molecular Diagnostics Drive Myriad's (MYGN) Q2 Earnings?
by Zacks Equity Research
Myriad (MYGN) positioned to deliver solid Q2 results on the diversified Molecular Diagnostics portfolio with products like GeneSight and EndoPredict tests.
Is AmerisourceBergen (ABC) Poised for a Beat in Q1 Earnings?
by Zacks Equity Research
AmerisourceBergen's (ABC) Q1 results are expected to gain on strength in pharmaceutical distribution segment.
What's in Store for Pacific Biosciences (PACB) in Q4 Earnings?
by Zacks Equity Research
Pacific Biosciences (PACB) is likely to witness year-over-year decline in product revenues.
What to Expect From Quest Diagnostics (DGX) in Q4 Earnings
by Zacks Equity Research
Quest Diagnostics (DGX) spots a slight turnaround of its sluggish revenue per requisition performance only in the last couple of quarters.
Can Baxter (BAX) Beat Q4 Earnings on Hospital Products?
by Zacks Equity Research
Baxter International (BAX) is expected to gain from strength in Hospital Products segment on solid sales in the U.S. Fluid Systems business as well as growing demand for injectable pharmaceuticals.
Can IDEXX (IDXX) Post a Beat in Q4 Earnings on CAG Strength?
by Zacks Equity Research
IDEXX Laboratories (IDXX) is poised to gain from strength in CAG Diagnostics business in Q4.
Will WATCHMAN Boost Boston Scientific's (BSX) Q4 Earnings?
by Zacks Equity Research
Boston Scientific (BSX) witnesses improvement in IC arm on an innovative portfolio and robust commercial teams. The WATCHMAN platform is likely to impress with another solid quarterly performance.
Edwards Lifesciences' (EW) THVT Likely to Drive Q4 Earnings
by Zacks Equity Research
Edwards Lifesciences (EW) is expected to gain from strength in THVT on continued therapy adoption across all geographies.
Will S.E.T. Arm Drive Zimmer Biomet's (ZBH) Q4 Earnings?
by Zacks Equity Research
Zimmer Biomet (ZBH) poised to gain on strength in S.E.T as well as Spine & CMF segments in Q4.
Illumina's (ILMN) Q4 Earnings to Show Growth in All Lines
by Zacks Equity Research
Illumina (ILMN) expected to gain from strong revenues at Product as well as Service and other revenue segments in Q4.